EGFR and non-small cell lung carcinoma: Given the hyperactivation of the IL-6/JAK/STAT3 pathway in EGFR-mutated NSCLC, feedforward activation of the IL-6/JAK/STAT3 pathway in the presence of EGFR TKIs, and synergistic activity of JAK inhibition with EGFR TKIs in EGFR-mutant models, we conducted a phase 1b study of the combination of first-generation EGFR TKI erlotinib plus the JAK1/2 and TANK-binding kinase 1 (TBK1) inhibitor momelotinib in patients with EGFR TKI-naive, EGFR-mutated advanced NSCLC.